Shionogi & Co., Ltd. (TYO:4507)
Japan
· Delayed Price · Currency is JPY 3,180.00
+105.00 (3.41%)
Apr 28, 2026, 3:30 PM JST
Shionogi & Employees
Shionogi & had 4,955 employees as of March 31, 2025. The number of employees decreased by 4 or -0.08% compared to the previous year.
Employees
4,955
Change (1Y)
-4
Growth (1Y)
-0.08%
Revenue / Employee
93.92M JPY
Profits / Employee
39.32M JPY
Market Cap
2,706.10B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Eisai | 10,917 |
| Takeda Pharmaceutical Company | 47,455 |
| Sumitomo Pharma | 3,832 |
| Hisamitsu Pharmaceutical Co. | 2,799 |
| Nippon Shinyaku | 2,243 |
| Toho Holdings | 7,609 |
| Tsumura & Co. | 4,272 |
| Sawai Group Holdings | 3,310 |
Shionogi & News
- 20 days ago - Shionogi Receives Contract with U.S. Government Through BARDA's Project BioShield to Enhance National Preparedness for Drug-Resistant Bacterial Threats - Business Wire
- 27 days ago - Shionogi Completes Acquisition of All Rights to RADICAVA (edaravone) - Business Wire
- 27 days ago - GSK Announces Completion Of Pfizer's Exit Of Its Investment In ViiV Healthcare - Nasdaq
- 5 weeks ago - Shionogi Announces First Patients Enrolled in Global Phase 2 Clinical Trial in Adults with Late-Onset Pompe Disease - Business Wire
- 3 months ago - Japan's Shionogi boosts ViiV stake to 21.7% as Pfizer exits - Reuters
- 2 years ago - Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease - Business Wire